Funding for this research was provided by:
National Institute on Aging (UF1AG032438, AG046374)
Foundation for Biomedical Research and Innovation
DIAN Expanded Registry
DIAN-TU Pharma Consortium
Gerald and Henrietta Rauenhorst Foundation
Text and Data Mining valid from 2018-07-18
Received: 6 February 2018
Accepted: 30 May 2018
First Online: 18 July 2018
Ethics approval and consent to participate
: The Washington University Institutional Review Board reviewed the study protocol (IRB no. 201111194). All subjects included in this study, or their proxies, gave written informed consent.
: AMG is a member of the scientific advisory board for Denali Therapeutics and serves on a genetic scientific advisory panel for Pfizer. RJB receives laboratory research funding from the National Institutes of Health, the Alzheimer’s Association, the BrightFocus Foundation, the Rainwater Foundation Tau Consortium, the Association for Frontotemporal Degeneration, the Cure Alzheimer’s Fund, and the tau SILK Consortium (AbbVie, Biogen, and Eli Lilly and Co.). Funding for clinical trials not related to this research include the National Institutes of Health, the Alzheimer’s Association, Eli Lilly and Co., Hoffman La-Roche, Janssen, Avid Radiopharmaceuticals, the GHR Foundation, and an anonymous foundation. RJB also receives research funding from the DIAN Pharma Consortium (AbbVie, Amgen, AstraZeneca, Biogen, Eisai, Eli Lilly and Co., Hoffman La-Roche, Janssen, Pfizer, and Sanofi). RJB has received honoraria from Janssen and Pfizer as a speaker and from Merck and Pfizer as an advisory board member. Washington University, RJB, and DMH have equity ownership interest in C2N Diagnostics and receive royalty income based on technology (stable isotope labeling kinetics and blood plasma assay) licensed by Washington University to C2N Diagnostics. RJB receives income from C2N Diagnostics for serving on the scientific advisory board. Washington University, with RJB as coinventor, has submitted the U.S. nonprovisional patent application “Methods for measuring the metabolism of CNS derived biomolecules in vivo” and the provisional patent application “Plasma based methods for detecting CNS amyloid deposition.” The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.